World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 12 December 2020
Main ID:  NCT02897063
Date of registration: 07/09/2016
Prospective Registration: Yes
Primary sponsor: Vanderbilt University Medical Center
Public title: Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
Scientific title: The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2
Date of first enrolment: September 2016
Target sample size: 34
Recruitment status: Recruiting
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Double (Participant, Investigator).  
Phase:  Phase 1
Countries of recruitment
United States
Name:     Emily C Smith, RN
Telephone: 615-875-1516
Name:     Emily C Smith, RN
Telephone: 615.875.1516
Name:     Italo Biaggioni, MD
Affiliation:  Vanderbilt University Medical Center
Key inclusion & exclusion criteria

Inclusion Criteria:

- Male and female subjects, age 40-80 years with possible or probable Multiple System
Atrophy, Pure Autonomic Failure, or Parkinson disease, as defined by Consensus

- Neurogenic orthostatic hypotension defined as a =30-mmHg decrease in systolic blood
pressure within 3 minutes of standing associated with impaired autonomic reflexes
determined by autonomic testing in the absence of other identifiable causes.

- Subjects able and willing to provide informed consent.

Exclusion Criteria:

- Supine hypertension, defined as systolic blood pressure of = 160 mmHg measured on two
separate occasions.

- Pregnancy.

- Systemic illnesses known to produce autonomic neuropathy, including but not limited to
diabetes mellitus, amyloidosis, monoclonal gammopathies, and autoimmune neuropathies.

- History of known aortic aneurisms, thoracic, abdominal or pelvic surgery in the past 6

- Symptomatic abdominal or inguinal hernias.

- Severe gastroesophageal reflux.

- Recent fractures or fissures of ribs, thoracic or lumbar spine.

- Medical devices implanted on the abdominal wall or abdomen that would interfere with
the abdominal compression.

- Intolerance to any increase in intraabdominal pressure.

- Clinically unstable coronary artery disease or major cardiovascular or neurological
event in the past 6 months, and other factors which in the investigator's opinion
would prevent the subject from completing the protocol including clinically
significant abnormalities in clinical, mental or laboratory testing.

Age minimum: 40 Years
Age maximum: 80 Years
Gender: All
Health Condition(s) or Problem(s) studied
Autonomic Failure
Multiple System Atrophy
Orthostatic Hypotension
Parkinson Disease
Pure Autonomic Failure
Drug: Droxidopa
Drug: Midodrine
Drug: Placebo
Primary Outcome(s)
Stroke volume [Time Frame: Up to 10 min of head up tilt]
Secondary Outcome(s)
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history